RVW Wealth LLC Purchases 1,148,260 Shares of Milestone Pharmaceuticals Inc. $MIST

RVW Wealth LLC purchased a new position in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,148,260 shares of the company’s stock, valued at approximately $994,000.

Several other institutional investors also recently modified their holdings of the business. Seven Fleet Capital Management LP acquired a new stake in Milestone Pharmaceuticals in the first quarter valued at $397,000. TRU Independence Asset Management 2 LLC acquired a new position in Milestone Pharmaceuticals during the 2nd quarter worth about $201,000. Renaissance Technologies LLC acquired a new position in Milestone Pharmaceuticals during the 1st quarter worth about $154,000. ADAR1 Capital Management LLC bought a new stake in shares of Milestone Pharmaceuticals in the 2nd quarter valued at about $134,000. Finally, Guardian Wealth Advisors LLC NC grew its position in shares of Milestone Pharmaceuticals by 21.1% in the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 339,450 shares of the company’s stock valued at $455,000 after buying an additional 59,200 shares during the last quarter. Institutional investors own 86.18% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on MIST shares. HC Wainwright reissued a “buy” rating on shares of Milestone Pharmaceuticals in a research note on Thursday, September 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Tuesday, July 14th. Cantor Fitzgerald assumed coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, August 20th. They set an “overweight” rating and a $3.00 target price for the company. Finally, Zacks Research upgraded shares of Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $6.40.

Milestone Pharmaceuticals Trading Down 2.0%

Milestone Pharmaceuticals stock traded down $0.02 during trading hours on Tuesday, reaching $0.76. 1,389,908 shares of the company’s stock were exchanged, compared to its average volume of 1,815,313. The firm’s 50 day simple moving average is $1.04 and its 200 day simple moving average is $1.33. Milestone Pharmaceuticals Inc. has a twelve month low of $0.75 and a twelve month high of $3.06. The company has a quick ratio of 7.92, a current ratio of 8.13 and a debt-to-equity ratio of 3.25. The firm has a market capitalization of $95.14 million, a PE ratio of -1.11 and a beta of 1.01.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The firm had revenue of $0.56 million during the quarter, compared to the consensus estimate of $0.82 million. Research analysts predict that Milestone Pharmaceuticals Inc. will post -0.84 earnings per share for the current year.

Milestone Pharmaceuticals Profile

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular conditions. The company’s lead product candidate is etripamil, a short-acting calcium channel blocker formulated as a nasal spray and designed for rapid, patient-administered treatment.

Etripamil has been studied primarily for paroxysmal supraventricular tachycardia (PSVT), a condition characterized by episodes of abnormally rapid heart rate. The product is intended to provide patients with an option for treating episodes outside of a hospital or clinic, potentially reducing the need for emergency medical intervention.